Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis.

Hannelien Verbeke, Sofie Struyf, Nele Berghmans, Els Van Coillie, Ghislain Opdenakker, Catherine Uyttenhove, Jacques Van Snick, Jo Van Damme

Rega Institute for Medical Research, Laboratory of Molecular Immunology, K.U.Leuven, Leuven, Belgium.

Cancer letters 2011 Mar 1

filter terms:

The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases. Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Citation

Hannelien Verbeke, Sofie Struyf, Nele Berghmans, Els Van Coillie, Ghislain Opdenakker, Catherine Uyttenhove, Jacques Van Snick, Jo Van Damme. Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer letters. 2011 Mar 1;302(1):54-62